Search 

Mawdsleys are a UK based pharmaceutical wholesaler and leading partner to the healthcare sector and pharmaceutical industry. They offer a range of services:

Pharmaceutical Industry:-
Pharma Third Party Logistics (3PL)
Named Patient Medicine Distribution
Clinical Trial Logistics (inc. blinding, randomisation, labelling, global distribution)
Clinical Trial Materials sourcing & manufacture (inc. IMPs, placebos, over encapsulation)
Regulatory Affairs Services (inc. QP Release / batch certification, QP Services, RP Services)
Patient Information Testing

Healthcare Sector:-
Wholesale Services to hospitals
International Sales
Unlicensed / Named Patient Medicine Supply
Clinical Trial Supply to hospitals and academia (inc. placebos)
Pharmaceutical Overlabelling
Pharmacy IT systems

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets.

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.

Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.

It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

Mogrify® has developed a proprietary suite of platform technologies that utilise a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be $39 billion USD by 2023, Mogrify is commercialising its technology via a combination of internal cell and gene therapy development, co-development partnerships, and out-licensing of novel cell conversions. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.